Context: Hydrogen has emerged as a promising clean energy carrier, underscoring the imperative need to comprehend its adsorption mechanisms. This study delves into the magnetic and electronic properties of Co-Mo-P clusters, aiming to unveil their catalytic potential in hydrogen production. Employing density functional theory (DFT), we optimized cluster configurations and scrutinized their magnetic behaviors.
View Article and Find Full Text PDFContext: The article presents a comparative study of the electronic, magnetic and catalytic properties of CrPS, AlPS, GaPS and their expanded structures. It is finally found that: When n = 2, 3, the internal electron mobility of the configurations is stronger than when n = 0,1. When n = 1, the five configurations, except configuration 1Cr, are susceptible to both electrophilic and nucleophilic reactions at the same time.
View Article and Find Full Text PDFContext: The investigation of the stability, electronic properties, and catalytic activity of clusters CoMoP holds significant applications and implications in catalyst design, materials science, energy conversion and storage, and environmental protection. The study aims to delve into the unique features of the clusters CoMoP(n = 1 ~ 5), aiming to drive advancements in these related fields. The results obtained from the analysis revealed the stable configurations of the ten clusters, primarily characterized by steric structures.
View Article and Find Full Text PDFContext: The article explores and compares the electronic structure and magnetic properties of transition metal phosphate materials, namely FePS, CoPS, and NiPS.
Research Findings: Analysis of the optimized configuration reveals significant insights into the electronic properties of MPS clusters. Electrons within the cluster exhibit a flow from the metal atom M and the non-metal atom P to the non-metal atom S.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
September 2018
Objective To investigate the association of single nucleotide polymorphisms (SNPs) of signal transducer and activator of transcription 4 (STAT4) rs7574865 and miRNA146a rs2910164 with rheumatoid arthritis (RA) in Wuling mountain area. Methods 287 RA patients and 305 age-matched healthy controls were included. The rs7574865 and rs2910164 SNPs of RA patients and control subjects were measured by multiplex PCR combined with high throughput sequencing(HI-SNP).
View Article and Find Full Text PDFObjective: To investigate the chemical constituents from the ethanol extract of Patrinia villosa.
Methods: Various column chromatographic methods including silica gel and Sephadex LH-20 were used for the isolation and purification. Chemical structures were elucidated on the basis of spectroscopic analysis.
Objective: Raloxifene, a selective estrogen receptor modulator, reduces osteoporosis and invasive breast cancer risk but increases risk for venous thromboembolism and fatal stroke in women with or at high risk for coronary heart disease. To assess the risk/benefit of raloxifene as a preventative treatment, we analyzed treatment effects on overall and cause-specific mortality.
Methods: A pooled analysis of mortality data was performed from large clinical trials of raloxifene (60 mg/day) versus placebo, including the Multiple Outcomes of Raloxifene Evaluation/Continuing Outcomes Relevant to Evista studies (7705 postmenopausal osteoporotic women followed for 4 years and a subset of 4011 participants followed for an additional 4 years; 110 deaths) and the Raloxifene Use for the Heart trial (10,101 postmenopausal women with coronary disease or multiple risk factors for coronary disease followed for 5.
Purpose: Raloxifene reduces vertebral fracture and invasive breast cancer risks, but increases fatal strokes in postmenopausal women at increased coronary risk. We assessed whether this risk is concentrated in postmenopausal women already at high stroke risk.
Methods: Raloxifene Use for The Heart (RUTH) enrolled 10,101 postmenopausal women (mean age 67 years) with or at increased coronary heart disease risk; Multiple Outcomes of Raloxifene Evaluation (MORE) enrolled 7705 osteoporotic postmenopausal women (mean age 66 years).
Background: In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, was found to reduce the risk of invasive breast cancer and vertebral fractures but not the risk of cardiovascular events.
View Article and Find Full Text PDFObjective: To evaluate the relationship between bone mass and risk of breast cancer and to determine the effect of raloxifene therapy on breast cancer incidence in women categorized by bone mass into low bone mass and osteoporosis subgroups.
Design: In this post hoc analysis, data were analyzed from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, enrolling postmenopausal women with low bone mass (N = 7705), and the Continuing Outcomes Relevant to Evista (CORE) trial, a follow-up to MORE enrolling 4011 MORE participants. Total follow-up was for up to 8 years.
Aim: To determine the contribution of bone mineral density (BMD) to breast cancer risk relative to other established breast cancer risk factors in postmenopausal women with osteoporosis.
Methods: Data for this analysis comprised those collected from women randomized to placebo in the MORE and CORE trials (N = 2,576). Risk factors measured at baseline included age, family history of breast cancer, estradiol level, body mass index, prior hormone therapy, BMD and vertebral fracture status.
Unlabelled: In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE had limitations for assessing fracture risk. In a subset of 386 women, 7 years of raloxifene treatment significantly increased lumbar spine and femoral neck BMD compared from the baseline of MORE.
View Article and Find Full Text PDFIn laboratory validation studies, it is often important to assess agreement between two assays, based on different techniques. Oftentimes, both assays have lower limits of detection and thus measurements are left censored. For example, in studies of Human Immunodeficiency Virus (HIV), the branched DNA (bDNA) assay was developed to quantify HIV-1 RNA concentrations in plasma.
View Article and Find Full Text PDFIn clinical studies, assessing agreement of multiple readings on the same subject plays an important role in the evaluation of continuous measurement scale. The multiple readings within a subject may be replicated readings by using the same method or/and readings by using several methods (e.g.
View Article and Find Full Text PDFAccurate and precise measurement is an important component of any proper study design. As elaborated by Lin (1989, Biometrics 45, 255-268), the concordance correlation coefficient (CCC) is more appropriate than other indices for measuring agreement when the variable of interest is continuous. However, this agreement index is defined in the context of comparing two fixed observers.
View Article and Find Full Text PDF